DHI vs OptimizeRx
DHX and OPRX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DHX and OPRX compare
DHI is the larger company, worth 1.4 times as much as OptimizeRx ($192M against $138M).
On earnings, DHI is cheaper: it trades at 23.2× trailing earnings, against 28.2× for OptimizeRx.
DHI grew revenue faster over the last twelve months (−5.0% versus −14.0% for OptimizeRx).
DHI keeps more of each dollar of sales as profit, with a net margin of 6.3% compared with 5.3% at OptimizeRx.
DHI scores higher on the StockData Score (12 against 11 for OptimizeRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DHX | OPRX |
|---|---|---|
| Size and price | ||
| Market cap | $192M | $138M |
| Share price | $4.41 | $7.34 |
| Change, 1 year | 152% | −54.6% |
| Change, 5 years | −14.7% | −89.8% |
| Beta (5Y) | 0.95 | 1.94 |
| Employees | 270 | 104 |
| StockData Score | ||
| Total score | 12 (better) | 11 |
| Valuation score | 6 (better) | 3 |
| Growth score | 0 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 23.2× (better) | 28.2× |
| P/S | 1.5× | 1.5× (better) |
| P/B | 2.0× | 1.0× (better) |
| EV/EBITDA | 15.2× | 8.2× (better) |
| P/FCF | 8.6× | 7.0× (better) |
| FCF yield | 11.6% | 14.4% (better) |
| Fair value | $6.93 | $10.52 |
| Margin of safety | 36.3% (better) | 30.2% |
| Growth | ||
| Revenue growth (TTM) | −5.0% (better) | −14.0% |
| Revenue growth, 5Y average | 2.8% | 20.4% (better) |
| Net income growth (TTM) | – | 14656% |
| Profitability | ||
| Gross margin | 82.1% (better) | 75.3% |
| Operating margin | 11.6% | 12.2% (better) |
| Net margin | 6.3% (better) | 5.3% |
| FCF margin | 17.9% | 21.1% (better) |
| Return on equity | 8.3% (better) | 3.9% |
| Return on invested capital | 8.4% (better) | 5.5% |
| Financial health | ||
| Debt / equity | 0.32 | 0.10 (better) |
| Net debt / EBITDA | 1.86 (better) | −0.61 |
| Interest coverage | 6.1× (better) | 3.1× |
| Current ratio | 0.42 | 5.06 (better) |
| Altman Z-score | 2.16 | 3.39 (better) |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 7.6% | – |
| Shareholder yield | 7.6% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 70.5% | 59.6% |
| Held by insiders | 18.6% | 19.4% |
| Insider net buying, 12 months | −$265K | −$18.8K (better) |
| Short interest, % of float | 0.88% | 7.8% |
Go deeper
- DHX stock overview
- DHX income statement
- DHX valuation and score
- OPRX stock overview
- OPRX income statement
- OPRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.